Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Genomics02:02

Genomics

39.6K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
39.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repositioning of 3-(isoxazol-3-yl)thiazolidin-4-one-based compounds via Inverse Virtual Screening: discovery of new ERα inhibitors with in vitro activity in breast cancer models.

European journal of medicinal chemistry·2026
Same author

Artificial Intelligence-Assisted Quantification of Longitudinal HRCT Changes During Treatment of Pulmonary Tuberculosis: An Exploratory Proof-of-Concept Study.

Diagnostics (Basel, Switzerland)·2026
Same author

Cytomegalovirus in pregnancy: 20-year experience of a southern italy centre on diagnosis, prenatal surveillance, and neonatal outcomes.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Is Recurrent Endometriosis a Reprogrammed Disease? Molecular Persistence Beyond Surgical Clearance.

Cells·2026
Same author

Robotic Surgery in Gynecology: Balancing Clinical Benefit, Cost-Effectiveness, and Accessibility.

Journal of clinical medicine·2026
Same author

Sentinel Lymph Node Mapping with Indocyanine Green in Endometrial Cancer: Does the Minimally Invasive Platform Matter?

Journal of investigative surgery : the official journal of the Academy of Surgical Research·2026

Related Experiment Video

Updated: Jan 13, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics,

Martina Pierri1, Giovanni Ciani2, Maria Chiara Brunese2

  • 1Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.

Diagnostics (Basel, Switzerland)
|October 29, 2025
PubMed
Summary

Multi-omics technologies like genomics, metabolomics, and radiomics offer new insights into non-small cell lung cancer (NSCLC). Integrating these approaches aids in early diagnosis, personalized therapy, and improved clinical decision-making for lung cancer patients.

Keywords:
biomarkersgenomicsmetabolomicsmolecular diagnosticsnon-small-cell lung cancerradiomics

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

335
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.8K

Related Experiment Videos

Last Updated: Jan 13, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

335
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.8K

Area of Science:

  • Oncology
  • Genomics
  • Metabolomics
  • Radiomics

Background:

  • Multi-omics integration is revolutionizing cancer management.
  • Genomics, metabolomics, and radiomics provide insights into tumor biology, diagnosis, and therapy.
  • Non-small cell lung cancer (NSCLC) is a key focus for these advanced technologies.

Purpose of the Study:

  • To provide a comprehensive overview of omics approaches in NSCLC.
  • To highlight the applications of genomics, metabolomics, and radiomics in lung cancer.
  • To explore the potential of integrating these technologies for improved patient outcomes.

Main Methods:

  • Review of current omics technologies, including genomics, NMR-based metabolomics, and radiomics.
  • Analysis of the application of these methods in non-small cell lung cancer (NSCLC).
  • Exploration of the integration of genomic, metabolomic, and radiomic data.

Main Results:

  • Genomics identifies key genetic alterations driving NSCLC and its response to therapy.
  • Metabolomics reveals biomarkers for tumor burden, progression, and prognosis.
  • Radiomics quantifies tumor heterogeneity and predicts treatment response non-invasively.

Conclusions:

  • Integrating genomics, metabolomics, and radiomics enhances understanding of NSCLC biology.
  • These multi-omics approaches can lead to non-invasive predictive models and personalized therapies.
  • The combined use of omics technologies improves clinical decision-making for lung cancer patients, aiding early diagnosis and treatment selection.